The U.S. Environmental Protection Agency (EPA) is developing methods for utilizing computational chemistry, high-throughput screening (HTS), and various toxicogenomic technologies to predict potential for toxicity and prioritize limited testing resources toward chemicals that likely represent the greatest hazard to human health and the environment. This chemical prioritization research program, entitled ''ToxCast,'' is being initiated with the purpose of developing the ability to forecast toxicity based on bioactivity profiling. The proof-of-concept phase of ToxCast will focus upon chemicals with an existing, rich toxicological database in order to provide an interpretive context for the ToxCast data. This set of several hundred reference chemicals will represent numerous structural classes and phenotypic outcomes, including tumorigens, developmental and reproductive toxicants, neurotoxicants, and immunotoxicants. The ToxCast program will evaluate chemical properties and bioactivity profiles across a broad spectrum of data domains: physical-chemical, predicted biological activities based on existing structure-activity models, biochemical properties based on HTS assays, cell-based phenotypic assays, and genomic and metabolomic analyses of cells. These data will be generated through a series of external contracts, along with collaborations across EPA, with the National Toxicology Program, and with the National Institutes of Health Chemical Genomics Center. The resulting multidimensional data set provides an informatics challenge requiring appropriate computational methods for integrating various chemical, biological, and toxicological data into profiles and models predicting toxicity.
Across several U.S. Environmental Protection Agency (EPA) programs, there is a clear need to develop methods for evaluating large numbers of environmental chemicals for potential toxicity and to use the resulting information to prioritize the use of testing resources toward those chemicals and endpoints that present the greatest likelihood of risk to human health and the environment. This need can be addressed through the experience of the pharmaceutical industry in the use of state of the art, high-throughput screening (HTS), toxicogenomics, and computational chemistry tools for the discovery of new drugs (Table 1) , with appropriate adjustments to the needs of environmental toxicology. Thus, a research program entitled ''ToxCast'' has been initiated within EPA to develop an ability to forecast toxicity based on bioactivity profiling. Ultimately, ToxCast's purpose is to develop methods of prioritizing chemicals for further screening and testing to assist EPA programs in the management and regulation of environmental contaminants.
Over the past decade, HTS has developed into a primary tool for drug discovery based upon bioactivity screening of the drugable proteome (Fliri et al., 2005b; Janzen and Hodge, 2006) . On a more limited scale, HTS has also been adapted to agrochemical discovery for the analysis of target species and model organisms (Smith et al., 2005; Tietjen et al., 2005) . Recently, HTS applications to toxicology have been expanding as a useful complement to traditional toxicology (Bhogal et al., 2005; Fliri et al., 2005a; Kikkawa et al., 2006) . In the federal sector, the National Institutes of Health Chemical Genomics Center (NCGC) has been established (http://www.ncgc.nih. gov/). The NCGC is using industrial-scale HTS technologies to collect data that is useful for developing small-molecule chemical probes for basic biological research (Austin et al., 2004) .
Traditional toxicology testing involves screening compounds through in vivo and in vitro tests focused on defined endpoints (e.g., neurotoxicity, developmental toxicity) or mechanisms of action (e.g., mutagenicity, cytotoxicity, regenerative hyperplasia). However, EPA is confronted with a large number of compounds to evaluate and faced with the difficulty of prioritizing scarce resources. Thus, environmental toxicology is challenged by (1) too many compounds to evaluate through endpoint-based in vivo testing and (2) inadequate models or knowledge of mechanism for many types of toxicity to design suitable in vitro testing. These challenges are also faced by other organizations including the U.S. Food and Drug Administration, European Union member countries, the Organization for Economic Cooperation and Development, and the regulated community (i.e., the pharmaceutical, agrochemical, and consumer products industries). There is an important need to distinguish between compounds that present little or no concern from those with the greatest likelihood of causing an adverse effect in the target species. High-throughput, high-content, and toxicogenomic screening methods applied to predictive toxicology provide opportunities for addressing these challenges.
The underlying hypothesis for ToxCast is that toxicological response is driven by interactions between chemicals and biomolecular targets. In most cases, these targets are part of the cellular proteome (e.g., receptors, ion channels, kinases). However, for most environmental chemicals the protein targets and biological effects underlying potential adverse effects have yet to be defined or characterized. Because suitable assays to query these have remained elusive, a more global approach of bioactivity profiling is a critical goal in environmental toxicology. This goal is embodied in the ToxCast program, which will focus on a multiple target matrix approach rather than a single target, directed vector approach. The matrix contains an expanded number of potential targets whose chemical interactions may be characterized by in silico models, biochemical assays, cell-based in vitro assays, and nonmammalian animal models.
ENABLING HTS AND TOXICOGENOMICS TECHNOLOGIES
Modern computational chemistry and molecular and cellular biology tools allow researchers to characterize a broad spectrum of physical and biological properties for large numbers of chemicals (Bredel and Jacoby, 2004;  Table 1 ). Genomics, transcriptomics, proteomics, and metabolomics technologies are components of this modern molecular biology toolkit. However, though omics technologies produce large amounts of data per sample, they are not truly high throughput, and the per chemical cost can be significant. Thus, the primary driver transforming drug discovery has been HTS technologies (Macarron, 2006) . HTS is comprised of assays in miniaturized format that can be either target or phenotype based. Target-based assays usually measure either binding or function of proteins Berg et al. (2006) BioMAP profiling based on activity of~100 drugs in cell-based assays designed to incorporate biological complexity Fliri et al. (2005b) Biological activity spectra for 1567 compounds (primarily drugs) based on interactions with 92 ligand-binding assays Fliri et al. (2005a) Utility of biological activity spectra for predicting drug-induced adverse effects Melnick et al. (2006) Effects of 1400 kinase inhibitors on panel of 35 tyrosine kinase-dependent cellular assays in dose-response format O' Brien et al. (2006) High-content screening of > 600 compounds in HepG2 cells demonstrated human toxicity potential with 80% sensitivity and 90% specificity Scherf et al. (2000) Correlated gene expression changes with drug activity patterns in 60 human cell lines-one of first to integrate large amounts of genomic and pharmacology data Smith et al. (2005) Application of HTS to agrochemical discovery Tietjen et al. (2005) HTS assays for development of new herbicides, insecticides, and fungicides included use of technologies capable of evaluating > 200,000 chemicals per year Walum et al. (2005) Combination of HTS in combination with basic biokinetic information to improve identification of toxic compounds Chemoinformatic surveys Richard et al. (2006) Public initiatives accelerating integration of diverse biological information with standardized chemical structure annotation Yang et al. (2006b) Strategy for mining structure-integrated toxicity databases to link chemical structure to biological endpoint Structure-activity studies Ekins et al. (2003) Public data on 1750 molecules to train computer models that predict inhibition of CYP2D6 and CYP3A4 O'Brien and DeGroot (2005)s Data for 58,963 compounds on human ether-a-go-go related gene channel and 2410 compounds on inhibition of CYP2D6 combined to create predictive model of toxicty Poroikov et al. (2003) Prediction of activity spectra for substances for total of 565 different outcomes, resulted in 64 million predictions on~25,000 chemicals in National Cancer Institute Open Database, used to select compounds for further testing 6 DIX ET AL.
cell free or in engineered cells. Phenotype-based assays monitor more complex endpoints in cells or whole organisms. These assays utilize small quantities of reagents and test chemicals and can be quite cost and time effective for analyzing larger numbers of chemicals. The ability to generate broad-based bioactivity profiles for large libraries of compounds in coordinated portfolios of biochemical and cellular assays has become the norm in the pharmaceutical sciences for drug discovery. As bioactivity profiles for compound libraries have grown, the potential of these profiles for identifying off-target mechanisms and potential liabilities has begun to emerge (Bhogal et al., 2005; Fliri et al., 2005b,c; Klekota et al., 2006; Melnick et al., 2006) . HTS technology optimized for drug discovery is now being refocused to applications in toxicological screening. It is important to appreciate, however, the significant and substantial differences between the application of HTS to pharmaceutical research versus environmental toxicology ( Table 2 ). The chemical space and numbers, the targeting and potency, and most importantly the intolerance for false negatives are all key differences that will impact assay selection and study design for ToxCast. The aim of drug discovery HTS is to find a small number of active compounds amenable to subsequent optimization for drug development, and in this pursuit, false negatives are generally not a major concern. HTS for toxicology must determine the activity of all compounds tested, and false negatives are of greater concern from a public safety standpoint.
ENVIRONMENTAL CHEMICALS RELEVANT TO TOXCAST
There are potentially 10,000 or more environmental chemicals from several EPA programs in need of prioritization for further testing. Antimicrobials, pesticidal inerts, high production volume (HPV: > 1 million lbs/year) chemicals, inventory update rule (> 10,000 lbs/year, < 1 million lbs/year) chemicals, and drinking water contaminant candidate list chemicals ( Fig. 1 ) generally have limited toxicological data available for hazard and risk assessments. As ToxCast moves beyond initial proofof-concept, thousands of environmental chemicals from various EPA domains can be considered for the ToxCast program. Looking beyond U.S. borders, there may be utility for a program like ToxCast in Europe's Registration, Evaluation, and Authorization of Chemicals (REACH) program. In 2003, the European Commission adopted the REACH proposal as a new regulatory framework for chemicals manufactured or imported at more than 1 ton per year. After final adoption of the REACH legislation, which is expected by the end of 2006, REACH legislation is likely to be in force by mid 2007 (http:// ec.europa.eu/environment/chemicals/reach/reach_intro.htm).
For the ToxCast proof-of-concept, conventional chemical pesticide actives are an ideal set of compounds for a number of reasons. Currently, registered pesticide actives are relatively modest in number (about 800), yet these actives represent a fairly diverse set of structural classes (Table 3) . Furthermore, these chemicals were all designed to have biological activity targeted against a pest species. This biological activity promises to provide a diverse range of positive results in the biochemical and cellular assays of ToxCast. Most importantly for the purposes of ToxCast, the pesticide actives have a wealth of uniform toxicological test data to inform hazard characterization. This existing information, and EPA's evaluation and interpretation of these data in current risk assessments, will 
DESIGN OF THE TOXCAST RESEARCH PROGRAM
ToxCast is designed to populate multiple data domains of increasing biological relevance and experimental cost, from in silico to in vitro, and perhaps even in vivo with nonmammalian model organisms (Fig. 2) . Associations between data domains and across chemicals can be made in order to generate bioactivity fingerprints and to group or bin chemicals. It is these larger patterns gleaned from bioactivity profiling across a broad range of assays that can be associated with either chemical structure (Fliri et al., 2005b,c; Melnick et al., 2006) , or with known toxicity of reference chemicals in a proof-of-concept study. It is from these associations or correlations between chemical structure, bioactivity profile, and toxicity outcome that the predictive power of ToxCast will be derived. The chemical and biological diversity in ToxCast will afford an opportunity to establish qualitative connections and quantifiable linkages between chemical structure, biological activity, and known or predicted toxicity.
In the course of identifying screening targets (Table 4) or assays suitable for ToxCast (Table 5) , two key considerations are the technical and economic feasibility of pursuing that target or assay for thousands of chemicals. Rather than just the   FIG. 2 . The multiple data domains that will comprise the ToxCast research program increase in both biological relevance and cost, along the continuum from in silico to in vitro to in vivo models. Associations between data domains, and across chemicals, will be used to bin or group chemicals with similar bioactivity profiles. drugable proteome, ToxCast sets out to survey a broad spectrum of genes, proteins, and metabolites that comprise the cellular ''interactome.'' Pathway-based analyses may also identify effects on higher level signaling, in addition to discrete targets within the cellular interactome. These pathways could serve as a good middle ground between biochemical or other targetfocused assays and more phenomenological, phenotypic, or highcontent assays. Thus, the range of potential targets and assays is very broad, and increasing biological relevance will have to be balanced against increasing cost for various data domains (Fig. 2) . Two abiding requirements for ToxCast assays will be the ability to minimize false negatives relating to hazards to human health and the current availability of these assays from reliable sources.
The majority of ToxCast data will come from a diverse series of assay types that collectively evaluate a broad spectrum of bioactivities (Fig. 3) . Like prior examples in the literature (Fliri et al., 2005c; Janzen and Hodge, 2006; Melnick et al., 2006) , ToxCast data will include numerous HTS assays delineating biological effects. Eventually, ToxCast is designed to research thousands of chemicals, requiring a managed library of environmental chemicals and sophisticated chemical and biological informatics to identify meaningful data associations. HTS biochemical assays will be supplemented by cellular assays for more complex biological effects and toxicities (Table 4, Schwartz et al., 2004) , and the zebrafish Danio rerio will be explored as models of mammalian toxicity. Biological samples from these various in vitro and in vivo assays will also be utilized for supplemental genomics and metabolomics.
While much of the ToxCast data are likely to come from HTS enzyme and receptor assays, an important complement to these data will be derived from assays using complex formats of human, nonhuman primate, or rodent cells for detecting biotransformation and complex toxicities. These are capable of detecting secondary effects (e.g., altered membrane permeability) resulting from chemically induced perturbations of the interactome. For example, in vitro primary hepatocyte models of the liver are commonly used to screen for metabolism and toxicity of xenobiotics, but primary hepatocytes rapidly lose liver-specific functions under standard cell culture conditions. Advances in tissue engineering and in silico modeling are enabling development of novel engineered approaches (Allen et al., 2005; Sivaraman et al., 2005) that could improve chemical hazard testing by recreating the three-dimensional microscale of the liver. Such tissue engineering raises new possibilities for the study of complex toxicological processes in vitro (Griffith and Swartz, 2006) , and the convergence of HTS and toxicogenomic data with systems biology is creating opportunities for developing bioengineered and computational models that more realistically replicate hepatic architecture and function. Toward this end, ToxCast could provide critical data for defining processes such as nuclear receptor-mediated regulation of xenobiotic-metabolizing enzymes, useful to systems biology models of toxicity. It is through systems biology that the issue of metabolism and biotransformation may be best addressed within ToxCast. A recent workshop organized by the European Center for the Validation of Alternative Methods (Coecke et al., 2006) emphasized the need to account for biotransformation with appropriate methods and to consider how such information can be incorporated into computer models for hazard identification.
Toxicogenomic assays, specifically the highly parallel profiling of gene expression and cellular metabolites in ToxCast biological samples can be an important adjunct or alternative to biochemical HTS profiling. For example, nuclear receptor binding and activity could be assessed by monitoring expression of suites of genes that are the transcriptional targets for specific nuclear receptors of interest. The appropriate target genes can be identified by a complementary suite of positive internal control ligands (e.g., testosterone for the androgen receptor, rifampicin for the human pregnane X receptor) utilized in ToxCast cellular assays. Receptor activities could then be assessed based on expression of receptor-modulated genes and utilized as an efficient toxicogenomics in vitro assay for characterization of environmental chemicals (Yang et al., 2006a) .
SELECTION OF PROOF-OF-CONCEPT CHEMICALS
The essential first step for the ToxCast program is to conduct a demonstration phase using reference chemicals that have an existing, rich toxicological database (i.e., registered chemical FIG. 3 . Data generation for the ToxCast program will begin with a managed chemical library, then flow from seven integrated types of analyses evaluating a broad spectrum of bioactivities. These data will be interpretively linked within the ToxCast database and a structured strategy developed to predict toxicity.
TOXCAST CHEMICAL PRIORITIZATION 9 pesticide actives). Several hundred reference chemicals representative of differing structural classes and phenotypic outcomes (e.g., carcinogens, reproductive toxicants, neurotoxicants) will need to be evaluated in ToxCast's wide net of assays and endpoints for this proof-of-concept. As the program matures, the assays and endpoints may be narrowed or modified based on predictive value, derived from associations between various data domains and the known toxicological properties of the reference chemicals. From this proof-of-concept, a broader strategy for identifying toxicity potential, minimizing false negatives, and prioritizing subsequent testing can be developed for larger number of environmental chemicals having limited toxicological data. This proof-of-concept will be especially important because of the challenges of ToxCast, as compared to conventional drug discovery, attributable in part to the diversity of environmental chemicals and issues relating to solubility, volatility, or confounding cytotoxicity.
Working from EPA databases, 826 conventional chemical pesticide actives that are currently registered or undergoing registration were identified. Of these 826, at least 270 are fooduse pesticides that have the most extensive testing requirements. Table 3 presents EPA's Office of Pesticide Programs (OPP) use categories and chemical classes for the majority of these pesticides. Table 5 lists the general selection criteria that were used for ranking chemical pesticide actives as candidates for the ToxCast proof-of-concept. Structural annotation was added to these pesticide actives, and further chemoinformatic analysis was conducted using LeadScope Enterprise (http:// www.leadscope.com; Table 6 ). These 785 chemicals were characterized into 101 structural classes, with 28 of these classes being singletons. For proof-of-concept, the chemicals were prioritized based on several criteria. High priority was generally given to those chemicals in common with the 1408 chemicals that the National Toxicology Program (NTP) has provided NCGC in early 2006 for HTS. Compatibility with standard HTS assays was also considered; thus, low priority was given to inorganics, organometallics, high ALogP (octanol/water partitioning), and molecular weights < 150. The 328 prioritized chemicals were secondarily ranked in descending order of representation in other toxicological databases annotated in the EPA DSSTox Structure Data File collection (http://www.epa.gov/ncct/dsstox/index.html), or in other EPA programs (e.g., industrial HPV chemicals) that correlate in some fashion to ToxCast. A small minority of inorganics and organometallics are included in this set of 328 chemicals because of their relevance to other toxicological programs. The remaining chemicals included an additional 219 chemical pesticides that might be suited to HTS.
INTEGRATING CHEMICAL AND BIOLOGICAL DATA TO FORECAST TOXICITY
Within ToxCast, data will be generated on an environmental chemical library using numerous types of assays evaluating a broad spectrum of bioactivities (Fig. 3) . These data will need to be relationally linked within the ToxCast database to other physical-chemical, toxicological, and in silico information, and a structured strategy developed to predict toxicity based on this entire data set. This structured strategy will be forged upon the known toxicities of the proof-of-concept chemical pesticides.
We are currently in the process of collecting toxicological data on pesticides and working with the OPP on how to accurately and precisely capture this information into a relational database. The OPP evaluates submitted toxicological studies in a standardized review process, which is captured in a Data Evaluation Record (DER). Information is being culled from DERs on endpoints, dose-response, and critical effects in mammalian test species for approximately 400 chemical pesticides. 
FIG. 4.
The application of ToxCast data to the process of prioritizing environmental chemicals based on hazard prediction: chemicals given a low priority may enter into no further testing, medium priorities may be recycled into ToxCast for further evaluation, and high priorities recommended for further screening and testing.
The DERs being used are primarily from neurotoxicity, developmental, reproductive, subchronic, chronic, and cancer guideline toxicology tests. The OPP conventional toxicology for the proof-of-concept pesticides will complement the chemoinformatic, HTS, and toxicogenomic information in the ToxCast database, allowing us to develop and validate ToxCast's predictive power. In addition, toxicological data from other EPA Programs (e.g., HPV Challenge) and the NTP will also be helpful in developing ToxCast. Throughout the course of methods and data development, our goal is to keep ToxCast a public and transparent enterprise.
Another ongoing informatics effort is aimed at generating, collating, reviewing, and organizing unambiguous definitions of chemical identity and structure for the various environmental chemical domains relevant to ToxCast and EPA. To accomplish this, we are building on the DSSTox project. This will also aid in the identification of other potentially useful sources of data relative to the ToxCast candidate chemical list, as well as help identify structurally similar chemicals for which toxicity or bioassay data might be available. Figure 4 presents a flowchart for applying ToxCast data and predictions to the process of prioritizing chemicals. Hazard prediction represents both the primary goal and the key bioinformatics and chemoinformatics challenge of this approach, and the value of such an approach is self-evident so long as false negatives are minimized. Over the past several years, a number of studies have been published presenting alternative, in vitro, and in some cases HTS methods for integrated testing of chemicals for bioactivity and associations with toxicity or side effects. One example relevant to ToxCast was an integrated, tiered approach using computational and experimental in vitro data for hazard assessment, although limited to only 10 environmental chemicals (Gubbels-van Hal et al., 2005) . The hazard assessment for these 10 substances was performed on the basis of available nonanimal data, quantitative structure activity relationship, physiologically based pharmacokinetic modeling, and additional new in vitro testing. Based on these data, predictions of various toxicities were made and then compared with prior in vivo testing to demonstrate at least a partial success. However, the limited number of chemicals included in the study of Gubbels-van Hal et al. did not allow conclusions to be drawn for the thousands of chemicals subject to REACH. It is apparent that methods compatible with larger numbers of chemicals, which do not lead to substantially higher costs for industry, need to be developed. We suggest that HTS technologies, larger chemical libraries, and expanded data analysis techniques may accomplish these broader goals within ToxCast.
CONCLUSIONS
The strategy of ToxCast encompasses a diverse range of data types. No single assay or endpoint will have a large impact on interpretation of the fingerprint or bioactivity profile. It will be the overall pattern across many assays and data types that will be the predictor of toxicity used for prioritizing chemicals. This will be the main goal of ToxCast, taking advantage of HTS and toxicogenomic technologies for bioactivity profiling of environmental chemicals related in structure or mechanism of action. Although the primary purpose is not to identify mechanisms of action of environmental toxicants per se, this might be a future benefit of the program. The availability of a biologically and chemically based system to categorize chemicals of like properties and activities will provide EPA Program Offices with a valuable tool that heretofore has been seriously lacking.
In late 2005, EPA organized the Chemical Prioritization Community of Practice (CPCP) to provide a forum for discussing the utility of computational chemistry, HTS, and various toxicogenomic technologies for chemical prioritization and Agency use. The CPCP has brought together experts and interested parties to discuss chemical prioritization research. This has afforded various groups the opportunity to consider the ToxCast concept, from EPA Program Offices, to external stakeholders such as the American Chemistry Council, the Center for Alternatives to Animal Testing, CropLife America and Environmental Defense. In addition, the CPCP has been helpful in building partnerships and communicating with the NTP, the NIEHS, and the NCGC.
Many hurdles remain to be cleared by ToxCast as it transits from concept to proof-of-concept and ultimately to a useful prioritization tool, including (1) accessing a chemical library providing coverage of sufficient chemical space, (2) identifying an upper limit on the per chemical cost of obtaining screening level data, (3) selecting assays within available resources that produce predictive bioactivity profiles, (4) evaluating the impact of metabolism on the efficiency and accuracy of assays, (5) developing a bioinformatic approach to mining ToxCast data and identifying predictive signatures, and (6) carrying out a prospective prioritization for chemicals currently entering a traditional testing process, in such a way that minimizes false negatives. These hurdles will be the focus of the ToxCast program over then next few years.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci. oxfordjournals.org/.
